Antibe Therapeutics Inc
TSX:ATE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pandox AB
STO:PNDX B
|
SE |
|
Roblon A/S
CSE:RBLN B
|
DK |
Antibe Therapeutics Inc
Total Liabilities & Equity
Antibe Therapeutics Inc
Total Liabilities & Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antibe Therapeutics Inc
TSX:ATE
|
Total Liabilities & Equity
CA$60.2m
|
CAGR 3-Years
27%
|
CAGR 5-Years
38%
|
CAGR 10-Years
42%
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Total Liabilities & Equity
$26.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-6%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Total Liabilities & Equity
CA$1.1B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
22%
|
|
|
Cronos Group Inc
TSX:CRON
|
Total Liabilities & Equity
$1.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
60%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Total Liabilities & Equity
$236.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
58%
|
CAGR 10-Years
95%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Total Liabilities & Equity
CA$1B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
Antibe Therapeutics Inc
Glance View
Antibe Therapeutics, Inc. is a biotechnology company, which engages in the development of medicines for pain and inflammation. The company is headquartered in Toronto, Ontario and currently employs 37 full-time employees. The company went IPO on 2013-06-18. The firm is focused on pain, inflammation, and regenerative medicine. The Company’s products pipeline includes Otenaproxesul, ATB-352, and ATB-340. Otenaproxesul is a novel anti-inflammatory drug that releases hydrogen sulfide and combines hydrogen sulfide with naproxen, non-steroidal, anti-inflammatory drug. ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen. ATB-340 is a gastrointestinal-safe version of low-dose aspirin for cardiovascular and cancer protection. The Company, through its wholly owned subsidiary, Citagenix Inc. (Citagenix) is a seller of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix’s portfolio consists of branded biologics and medical devices that promote bone regeneration.
See Also
What is Antibe Therapeutics Inc's Total Liabilities & Equity?
Total Liabilities & Equity
60.2m
CAD
Based on the financial report for Sep 30, 2023, Antibe Therapeutics Inc's Total Liabilities & Equity amounts to 60.2m CAD.
What is Antibe Therapeutics Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
42%
Over the last year, the Total Liabilities & Equity growth was -24%. The average annual Total Liabilities & Equity growth rates for Antibe Therapeutics Inc have been 27% over the past three years , 38% over the past five years , and 42% over the past ten years .
